- Home
- KOD vs AOMR Comparison
KOD vs AOMR Comparison
Compare KOD & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- AOMR
- Stock Information
- Founded
- KOD 2009
- AOMR 2018
- Country
- KOD United States
- AOMR United States
- Employees
- KOD N/A
- AOMR N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- AOMR Real Estate Investment Trusts
- Sector
- KOD Health Care
- AOMR Real Estate
- Exchange
- KOD Nasdaq
- AOMR Nasdaq
- Market Cap
- KOD 259.6M
- AOMR 237.8M
- IPO Year
- KOD 2018
- AOMR 2021
- Fundamental
- Price
- KOD $3.60
- AOMR $8.87
- Analyst Decision
- KOD Hold
- AOMR Strong Buy
- Analyst Count
- KOD 3
- AOMR 6
- Target Price
- KOD $9.00
- AOMR $11.75
- AVG Volume (30 Days)
- KOD 419.7K
- AOMR 169.6K
- Earning Date
- KOD 05-14-2025
- AOMR 05-05-2025
- Dividend Yield
- KOD N/A
- AOMR 14.41%
- EPS Growth
- KOD N/A
- AOMR N/A
- EPS
- KOD N/A
- AOMR 1.51
- Revenue
- KOD N/A
- AOMR $57,147,000.00
- Revenue This Year
- KOD N/A
- AOMR N/A
- Revenue Next Year
- KOD N/A
- AOMR $7.33
- P/E Ratio
- KOD N/A
- AOMR $5.87
- Revenue Growth
- KOD N/A
- AOMR N/A
- 52 Week Low
- KOD $1.92
- AOMR $7.36
- 52 Week High
- KOD $11.60
- AOMR $13.32
- Technical
- Relative Strength Index (RSI)
- KOD 49.07
- AOMR 37.62
- Support Level
- KOD $3.46
- AOMR $9.06
- Resistance Level
- KOD $3.81
- AOMR $9.40
- Average True Range (ATR)
- KOD 0.42
- AOMR 0.25
- MACD
- KOD -0.05
- AOMR -0.14
- Stochastic Oscillator
- KOD 46.20
- AOMR 0.00
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.